Ksaliproden

Izvor: Wikipedia
Ksaliproden
(IUPAC) ime
1-[2-(2-naftil)etil]-4-[3-(trifluorometil)fenil]-1,2,3,6-tetrahidropiridin
Klinički podaci
Identifikatori
CAS broj 135354-02-8
ATC kod N07XX03
PubChem[1][2] 128919
ChemSpider[3] 114237
UNII V8QL94KNQO YesY
KEGG[4] D06327 YesY
Hemijski podaci
Formula C24H22F3N 
Mol. masa 381,433 g/mol
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status

Ksaliproden (SR57746) je lek koji deluje kao 5HT1A agonist.[5] On ima neurotrofno i neuroprotektivno dejstvo in vitro,[6][7] i predložen je kao potencijalni tretman za nekoliko neurodegenerativnih oboljenja, među kojima su amiotrofična lateralna skleroza (ALS)[8] i Alchajmerova bolest.[9]

Reference[uredi - уреди]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. doi:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. doi:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. Joanne Wixon, Douglas Kell (2000). "Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG". Yeast 17 (1): 48–55. doi:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  5. Appert-Collin, A; Duong, FH; Passilly Degrace, P; Warter, JM; Poindron, P; Gies, JP (2005). "MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden". International journal of immunopathology and pharmacology 18 (1): 21–31. PMID 15698508. 
  6. Labie, C; Lafon, C; Marmouget, C; Saubusse, P; Fournier, J; Keane, PE; Le Fur, G; Soubrié, P (1999). "Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex". British Journal of Pharmacology 127 (1): 139–44. doi:10.1038/sj.bjp.0702545. PMC 1566010. PMID 10369466. 
  7. Duong, FH; Warter, JM; Poindron, P; Passilly, P (1999). "Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons". British Journal of Pharmacology 128 (7): 1385–92. doi:10.1038/sj.bjp.0702910. PMC 1571767. PMID 10602316. 
  8. Meininger, V; Bensimon, G; Bradley, WR; Brooks, B; Douillet, P; Eisen, AA; Lacomblez, L; Leigh, PN et al. (2004). "Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials". Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 5 (2): 107–17. doi:10.1080/14660820410019602. PMID 15204012. 
  9. Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). "Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats". Invest Radiol 37 (6): 321–7. doi:10.1097/00004424-200206000-00003. PMID 12021588. 

Spoljašnje veze[uredi - уреди]